Abstract

Multiple sclerosis (MS) is a common autoimmune neurological disease affecting patients' motor, sensory, and visual performance. Stem Cell Transplantation (SCT) is a medical intervention where a patient is infused with healthy stem cells with the purpose of resetting their immune system. SCT shows remyelinating and immunomodulatory functions in MS patients, representing a potential therapeutic option. We conducted this systematic review and meta-analysis that included randomized control trials (RCTs) of SCT in MS patients to investigate its clinical efficacy and safety, excluding observational and non-English studies. After systematically searching PubMed, Web of Science, Scopus, and Cochrane Library until January 7, 2024, nine RCTs, including 422 patients, were eligible. We assessed the risk of bias (ROB) in these RCTs using Cochrane ROB Tool 1. Data were synthesized using Review Manager version 5.4 and OpenMeta Analyst software. We also conducted subgroup and sensitivity analyses. SCT significantly improved patients expanded disability status scale after 2 months (N = 39, MD = - 0.57, 95% CI [- 1.08, - 0.06], p = 0.03). SCT also reduced brain lesion volume (N = 136, MD = - 7.05, 95% CI [- 10.69, - 3.4], p = 0.0002). The effect on EDSS at 6 and 12 months, timed 25-foot walk (T25-FW), and brain lesions number was nonsignificant. Significant adverse events (AEs) included local reactions at MSCs infusion site (N = 25, RR = 2.55, 95% CI [1.08, 6.03], p = 0.034) and hematological disorders in patients received immunosuppression and autologous hematopoietic SCT (AHSCT) (N = 16, RR = 2.33, 95% CI [1.23, 4.39], p = 0.009). SCT can improve the disability of MS patients and reduce their brain lesion volume. The transplantation was generally safe and tolerated, with no mortality or significant serious AEs, except for infusion site reactions after mesenchymal SCT and hematological AEs after AHSCT. However, generalizing our results is limited by the sparse number of RCTs conducted on AHSCT. Our protocol was registered on PROSPERO with a registration number: CRD42022324141.

© 2024. The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1 

PRISMA Flow chart of the…

Figure 2 

Risk of bias assessment: (…

Figure 3 

Forest plot of EDSS change…

Figure 4 

Forest plot of T25-FW change…

Figure 5 

Forest plot of radiological outcomes…

Similar articles

• Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

  Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.PMID: 36321557 Free PMC article.

• Stem cell therapy for dilated cardiomyopathy.

  Diaz-Navarro R, Urrútia G, Cleland JG, Poloni D, Villagran F, Acosta-Dighero R, Bangdiwala SI, Rada G, Madrid E.Cochrane Database Syst Rev. 2021 Jul 21;7(7):CD013433. doi: 10.1002/14651858.CD013433.pub2.PMID: 34286511 Free PMC article.

• Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis.

  Madani S, Amanzadi M, Aghayan HR, Setudeh A, Rezaei N, Rouhifard M, Larijani B.Syst Rev. 2022 May 2;11(1):82. doi: 10.1186/s13643-022-01950-3.PMID: 35501872 Free PMC article. Review.

• Stem cell transplantation for induction of remission in medically refractory Crohn's disease.

  El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O.Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2.PMID: 35556242 Free PMC article. Review.

• Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.

  Nabizadeh F, Pirahesh K, Rafiei N, Afrashteh F, Ahmadabad MA, Zabeti A, Mirmosayyeb O.Neurol Ther. 2022 Dec;11(4):1553-1569. doi: 10.1007/s40120-022-00389-x. Epub 2022 Jul 28.PMID: 35902484 Free PMC article.

See all similar articles

References

1. 1. Browne P, et al. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83:1022–1024. doi: 10.1212/WNL.0000000000000768. - DOI - PMC - PubMed
2. 1. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5:e00362. doi: 10.1002/brb3.362. - DOI - PMC - PubMed
3. 1. Lublin FD, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. - DOI - PMC - PubMed
4. 1. Wingerchuk DM, Carter JL. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin. Proc. 2014;89:225–240. doi: 10.1016/j.mayocp.2013.11.002. - DOI - PubMed
5. 1. Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J. Intern. Med. 2021;289:771–791. doi: 10.1111/joim.13215. - DOI - PMC - PubMed

References

1. 1. Browne P, et al. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83:1022–1024. doi: 10.1212/WNL.0000000000000768. - DOI - PMC - PubMed
2. 1. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5:e00362. doi: 10.1002/brb3.362. - DOI - PMC - PubMed
3. 1. Lublin FD, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. - DOI - PMC - PubMed
4. 1. Wingerchuk DM, Carter JL. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin. Proc. 2014;89:225–240. doi: 10.1016/j.mayocp.2013.11.002. - DOI - PubMed
5. 1. Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J. Intern. Med. 2021;289:771–791. doi: 10.1111/joim.13215. - DOI - PMC - PubMed
6. 1. Gavriilaki M, Sakellari I, Gavriilaki E, Kimiskidis VK, Anagnostopoulos A. Autologous hematopoietic cell transplantation in multiple sclerosis: Changing paradigms in the era of novel agents. Stem. Cells Int. 2019;2019:1–9. doi: 10.1155/2019/5840286. - DOI - PMC - PubMed
7. 1. Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front. Neurol. 2022;13:824926. doi: 10.3389/fneur.2022.824926. - DOI - PMC - PubMed
8. 1. Gholamzad M, et al. A comprehensive review on the treatment approaches of multiple sclerosis: Currently and in the future. Inflammation Res. 2019;68:25–38. doi: 10.1007/s00011-018-1185-0. - DOI - PubMed
9. 1. Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun. Rev. 2021;20:102826. doi: 10.1016/j.autrev.2021.102826. - DOI - PubMed
10. 1. Sharrack B, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: Updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc. Bone Marrow Transplant. 2020;55:283–306. doi: 10.1038/s41409-019-0684-0. - DOI - PMC - PubMed
11. 1. Zeng L, et al. Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): A systematic review and meta-analysis of randomized controlled trial. Stem Cells Int. 2022;2022:1–20. doi: 10.1155/2022/8513812. - DOI - PMC - PubMed
12. 1. Fassas A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study. Bone Marrow Transplant. 1997;20:631–638. doi: 10.1038/sj.bmt.1700944. - DOI - PubMed
13. 1. Snowden JA, et al. Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplant. 2012;47:770–790. doi: 10.1038/bmt.2011.185. - DOI - PMC - PubMed
14. 1. Muraro PA, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat. Rev. Neurol. 2017;13:391–405. doi: 10.1038/nrneurol.2017.81. - DOI - PubMed
15. 1. Karussis D, Kassis I. The potential use of stem cells in multiple sclerosis: An overview of the preclinical experience. Clin. Neurol. Neurosurg. 2008;110:889–896. doi: 10.1016/j.clineuro.2008.02.008. - DOI - PubMed
16. 1. Muraro PA, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 2005;201:805–816. doi: 10.1084/jem.20041679. - DOI - PMC - PubMed
17. 1. Markov A, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res. Ther. 2021;12:192. doi: 10.1186/s13287-021-02265-1. - DOI - PMC - PubMed
18. 1. Rahim F, Arjmand B. Stem cell clinical trials for multiple sclerosis: The past, present and future. Neurol. Regen. 2017 doi: 10.1007/978-3-319-33720-3_9. - DOI
19. 1. Oliveira AG, Gonçalves M, Ferreira H, Neves N. Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: A systematic review. Mult. Scler. Relat. Disord. 2020;38:101860. doi: 10.1016/j.msard.2019.101860. - DOI - PubMed
20. 1. Genc B, Bozan HR, Genc S, Genc K. Stem cell therapy for multiple sclerosis. Tissue Eng. Regen. Med. 2018 doi: 10.1007/5584_2018_247. - DOI
21. 1. Yousefi F, Lavi Arab F, Saeidi K, Amiri H, Mahmoudi M. Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection. J. Neuroimmunol. 2019;328:20–34. doi: 10.1016/j.jneuroim.2018.11.015. - DOI - PubMed
22. 1. Page MJ, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. - DOI - PMC - PubMed
23. 1. Higgins JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online) 2011;343:d5928–d5928. - PMC - PubMed
24. 1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. - DOI - PMC - PubMed
25. 1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444. - DOI - PubMed
26. 1. Motl RW, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Multiple Sclerosis. 2017;23:704–710. doi: 10.1177/1352458517690823. - DOI - PMC - PubMed
27. 1. Feys P, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Multiple Sclerosis. 2017;23:711–720. doi: 10.1177/1352458517690824. - DOI - PMC - PubMed
28. 1. Tombaugh TN. A comprehensive review of the paced auditory serial addition test (PASAT) Archiv. Clin. Neuropsychol. 2006;21:53–76. doi: 10.1016/j.acn.2005.07.006. - DOI - PubMed
29. 1. Higgins JPT, et al. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2019.
30. 1. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135. - DOI - PMC - PubMed
31. 1. Uccelli A, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021;20:917–929. doi: 10.1016/S1474-4422(21)00301-X. - DOI - PubMed
32. 1. Petrou P, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143:3574–3588. doi: 10.1093/brain/awaa333. - DOI - PubMed
33. 1. Lublin FD, et al. Human placenta-derived cells(pda-001) for the treatment of adults with multiple sclerosis: Arandomized, placebo-controlled, multiple-dose study. Mult. Scler. Relat. Disord. 2014;3:696–704. doi: 10.1016/j.msard.2014.08.002. - DOI - PubMed
34. 1. Llufriu S, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014;9:1–15. doi: 10.1371/journal.pone.0113936. - DOI - PMC - PubMed
35. 1. Li J-F, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23:113–122. doi: 10.3727/096368914X685005. - DOI - PubMed
36. 1. Fernández O, et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS One. 2018;13:1–14. doi: 10.1371/journal.pone.0195891. - DOI - PMC - PubMed
37. 1. Burt RK, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA J. Am. Med. Ass. 2019;321:165–174. doi: 10.1001/jama.2018.18743. - DOI - PMC - PubMed
38. 1. Mancardi GL, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2015;84:981–988. doi: 10.1212/WNL.0000000000001329. - DOI - PubMed
39. 1. Nabavi SM, et al. Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study. Mult. Scler. Relat .Disord. 2023;78:104895. doi: 10.1016/j.msard.2023.104895. - DOI - PubMed
40. 1. Freedman MS, et al. Treatment optimization in multiple sclerosis: canadian ms working group recommendations. Can. J. Neurol. Sci. 2020;47:437–455. doi: 10.1017/cjn.2020.66. - DOI - PubMed
41. 1. Rush CA, Maclean HJ, Freedman MS. Aggressive multiple sclerosis: Proposed definition and treatment algorithm. Nat. Rev. Neurol. 2015;11:379–389. doi: 10.1038/nrneurol.2015.85. - DOI - PubMed
42. 1. Rush CA, Atkins HL, Freedman MS. Autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis. Cold Spring Harb. Perspect. Med. 2019;9:a029082. doi: 10.1101/cshperspect.a029082. - DOI - PMC - PubMed
43. 1. Yanwu Y, Meiling G, Yunxia Z, Qiukui H, Birong D. Mesenchymal stem cells in experimental autoimmune encephalomyelitis model of multiple sclerosis: A systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2020;44:102200. doi: 10.1016/j.msard.2020.102200. - DOI - PubMed
44. 1. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. doi: 10.1186/1471-2377-14-58. - DOI - PMC - PubMed
45. 1. Kalincik T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138:3287–3298. doi: 10.1093/brain/awv258. - DOI - PubMed
46. 1. Ge F, Lin H, Li Z, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. Neurol. Sci. 2019;40:479–487. doi: 10.1007/s10072-018-3670-1. - DOI - PubMed
47. 1. Casanova B, et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: Comparison with secondary progressive multiple sclerosis. Neurol. Sci. 2017;38:1213–1221. doi: 10.1007/s10072-017-2933-6. - DOI - PMC - PubMed
48. 1. Genovese AV, et al. Atrophied brain T2 lesion volume at MRI is associated with disability progression and conversion to secondary progressive multiple sclerosis. Radiology. 2019;293:424–433. doi: 10.1148/radiol.2019190306. - DOI - PMC - PubMed
49. 1. Kearney H, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis. 2014;20:72–80. doi: 10.1177/1352458513492245. - DOI - PMC - PubMed
50. 1. Solaro C, et al. Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis. Mult. Scler. Relat. Disord. 2019;30:1–8. doi: 10.1016/j.msard.2019.01.043. - DOI - PubMed
51. 1. Castelo-Branco A, et al. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult. Scler. Relat. Disord. 2020;45:102420. doi: 10.1016/j.msard.2020.102420. - DOI - PubMed
52. 1. Ahmed Al-Anazi, K., K. Al-Anazi, W. & M. Al-Jasser, A. The Rising Role of Mesenchymal Stem Cells in the Treatment of Various Infectious Complications. Update on Mesenchymal and Induced Pluripotent Stem Cells (2020). 10.5772/intechopen.91475.
53. 1. Zhou Y, et al. Autologous mesenchymal stem cell transplantation in multiple sclerosis: A meta-analysis. Stem. Cells Int. 2019;2019:1–11. doi: 10.1155/2019/8536785. - DOI - PMC - PubMed
54. 1. Greco R, et al. Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties. Front. Immunol. 2019;10:5170. doi: 10.3389/fimmu.2019.01570. - DOI - PMC - PubMed
55. 1. Nabizadeh F, et al. Autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. Neurol. Ther. 2022;11:1553–1569. doi: 10.1007/s40120-022-00389-x. - DOI - PMC - PubMed
56. 1. Sormani MP, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2017;88:2115–2122. doi: 10.1212/WNL.0000000000003987. - DOI - PubMed
57. 1. Alexander T, Arnold R, Hiepe F, Radbruch A. Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases. Clin. Exp. Rheumatol. 2016;34:53–57. - PubMed

Publication types

• Systematic Review

• Meta-Analysis